2023 ASCO Annual Meeting — Focus on Myeloproliferative Neoplasms
The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting took place June 2 through June 6 in Chicago, Illinois. The meeting featured plenary sessions, posters, talks, and more updates on the latest research in hematologic oncology.
This section of news from the 2023 ASCO Annual Meeting focused on the latest developments in myeloproliferative neoplasms from the meeting, including updates from clinical trials, data on novel therapies, and more.
Advertisement
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
The phase II MANIFEST study suggested that pelabresib could be beneficial in myelofibrosis.
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
The authors concluded that treatment with INCB057643 monotherapy was generally well tolerated.
The case-control study used information from the Veterans Affairs Informatics and Computing Infrastructure database.
The study is designed to evaluate the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adults with ET.
Researchers followed the patients for three years after their final dose of luspatercept.
Jakatinib may be a new effective treatment option for patients with myelofibrosis.
Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of blood counts.
Selinexor plus ruxolitinib was effective in certain subgroups of patients with myelofibrosis.
In patients with Afib, MPNs are linked to an increased risk of hospital readmissions for bleeding and arterial thrombosis.
The pooled analysis set included patients from both arms of the intent-to-treat populations in SIMPLIFY-1 and SIMPLIFY-2.
The trial will enroll certain patients who had an "inadequate response” to ruxolitinib alone.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.